The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy

348 of 2283 patients with severe asthma>12 yrs. included in the real-life, long-term German Asthma Net registry used anti-IL5(R) antibody therapy (mepolizumab, benralizumab, reslizumab), (57±13 yrs., 57% female, BMI 27±6 kg/m², 5±5 exacerbations per year, ACQ score 2.6±1.5), compared to 329 corticosteroid (OCS) dependent patients (49±17 yrs., 55% female, BMI 27±6 kg/m², 4±4 exac./year, ACQ 2.6±1.4).